ae37 peptide vaccine
Biologicalexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 3, 2019 (NCT04024800)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04024800 | Phase 2 | May 3, 2019 | Generex Biotechnology Corp., Merck, NSABP Foundation |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Generex Biotechnology Corp. | For profit | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| NSABP Foundation | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1